A Proposal for the Comprehensive Care of Men on Androgen Deprivation Therapy: Recommendations From the Multidisciplinary Prostate Cancer 360 Working Group

被引:3
|
作者
Crawford, E. David [1 ,15 ]
Garnick, Marc B. [2 ]
Eckel, Robert H. [3 ]
Miner, Martin M. [4 ]
Freedland, Stephen J. [5 ]
Pachynski, Russell K. [6 ]
Wassersug, Richard J. [7 ]
Rosenberg, Matthew T. [8 ]
Walker, Lauren M. [9 ]
Fairman, Ciaran [10 ]
Curley, Tracy [11 ]
Crosby, Michael [12 ]
Lin, Pao-Hwa [13 ]
Hafron, Jason M. [14 ]
机构
[1] Univ Calif San Diego, Dept Urol, La Jolla, CA USA
[2] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA USA
[3] Univ Colorado Denver, Anschutz Med Ctr, Div Endocrinol Metab & Diabet, Aurora, CO USA
[4] Brown Univ, Warren Alpert Sch Med, Providence, RI USA
[5] Cedars Sinai Med Ctr, Ctr Integrated Res Canc & Lifestyle, Los Angeles, CA USA
[6] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA
[7] Univ British Columbia, Vancouver, BC, Canada
[8] Midmichigan Hlth Ctr, Jackson, MI USA
[9] Univ Calgary, Dept Oncol, Dept Psychol, Calgary, AB, Canada
[10] Univ South Carolina, Dept Exercise, Columbia, SC USA
[11] Mem Sloan Kettering Canc Ctr, New York, NY USA
[12] Vet Prostate Canc Awareness Inc, San Diego, CA USA
[13] Duke Univ, Sch Med, Dept Med, Durham, NC USA
[14] Michigan Inst Urol, West Bloomfield, MI USA
[15] Univ Calif San Diego, Dept Urol, Koman Family Outpatient Pavilion, La Jolla, CA 92037 USA
关键词
prostatic neoplasms; hormonal therapy; adverse effects; quality of life; lifestyle risk reduction; QUALITY-OF-LIFE; STYLE DIETARY PATTERN; CARDIOVASCULAR-DISEASE; RISK; MODALITIES; FRACTURE; FATIGUE; PATIENT;
D O I
10.1097/UPJ.0000000000000473
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction:To promote comprehensive care of patients throughout the androgen deprivation therapy (ADT) prescribing process, the Prostate Cancer 360 (PC360) Working Group developed monitoring and management recommendations intended to mitigate or prevent ADT-associated adverse events.Methods:The PC360 Working Group included 14 interdisciplinary experts with a dedicated clinical interest in prostate cancer and ADT management. The working group defined challenges associated with ADT adverse event management and then collaboratively developed comprehensive care recommendations intended to be practical for ADT prescribers.Results:The PC360 Working Group developed both overarching recommendations for ADT adverse event management and specific recommendations across 5 domains (cardiometabolic, bone, sexual, psychological, and lifestyle). The working group recommends an interdisciplinary, team-based approach wherein the ADT prescriber retains an oversight role for ADT management while empowering patients and their primary and specialty care providers to manage risk factors. The PC360 recommendations also emphasize the importance of proactive patient education that involves partners or other support providers. Recommended monitoring and assessment tools, risk factor management, and patient counseling points are also included for the 5 identified domains, with an emphasis on lifestyle and behavioral interventions that can improve quality of life and reduce the risk for ADT-associated complications.Conclusions:Comprehensive care of patients receiving ADT requires early and ongoing coordinated management of a variety of health domains, including cardiometabolic, bone, sexual, psychological health. Patient education and primary care provider involvement should begin prior to ADT initiation and continue throughout treatment to improve patient and partner quality of life.
引用
收藏
页码:18 / 29
页数:14
相关论文
共 50 条
  • [31] Cessation of Primary Androgen Deprivation Therapy for Men With Localized Prostate Cancer
    Fujimoto, Naohiro
    Kubo, Tatsuhiko
    Tomisaki, Ikko
    CLINICAL GENITOURINARY CANCER, 2015, 13 (04) : 359 - 363
  • [32] Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy
    Braga-Basaria, M.
    Muller, D. C.
    Carducci, M. A.
    Dobs, A. S.
    Basaria, S.
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2006, 18 (05) : 494 - 498
  • [33] Cognitive Effects of Androgen Deprivation Therapy in Men With Advanced Prostate Cancer
    Gunlusoy, Bulent
    Ceylan, Yasin
    Koskderelioglu, Asli
    Gedizlioglu, Muhtesem
    Degirmenci, Tansu
    Ortan, Pinar
    Kozacioglu, Zafer
    UROLOGY, 2017, 103 : 167 - 171
  • [34] Impact of androgen deprivation therapy on cognitive function in men with prostate cancer
    Yamamoto, Yutaka
    Akashi, Yasunori
    Kiba, Keisuke
    Hirayama, Akihide
    Uemura, Hirotsugu
    BJUI COMPASS, 2024, 5 (03): : 356 - 358
  • [35] Androgen-Deprivation Therapy and Metabolic Syndrome in Men With Prostate Cancer
    Harrington, Joanne M.
    Schwenke, Dawn C.
    Epstein, Dana R.
    Bailey, Donald E., Jr.
    ONCOLOGY NURSING FORUM, 2014, 41 (01) : 21 - 29
  • [36] Use of androgen deprivation therapy for metastatic prostate cancer in older men
    Keating, Nancy L.
    O'Malley, A. James
    McNaughton-Collins, Mary
    Oh, William K.
    Smith, Matthew R.
    BJU INTERNATIONAL, 2008, 101 (09) : 1077 - 1083
  • [37] Adverse bone effects in men with prostate cancer on androgen deprivation therapy
    Krupski, TL
    Smith, MR
    Lee, WC
    Pashos, CL
    Brandman, J
    Wang, Q
    Botteman, M
    Litwin, MS
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (09) : 1581 - 1581
  • [38] Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer
    Saigal, Christopher S.
    Gore, John L.
    Krupski, Tracey L.
    Hanley, Janet
    Schonlau, Matthias
    Litwin, Mark S.
    CANCER, 2007, 110 (07) : 1493 - 1500
  • [39] Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
    Smith, Matthew R.
    Egerdie, Blair
    Toriz, Narciso Hernandez
    Feldman, Robert
    Tammela, Teuvo L. J.
    Saad, Fred
    Heracek, Jiri
    Szwedowski, Maciej
    Ke, Chunlei
    Kupic, Amy
    Leder, Benjamin Z.
    Goessl, Carsten
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (08): : 745 - 755
  • [40] FRAX® assessment of men treated with androgen deprivation therapy for prostate cancer
    Turo, R.
    Cross, W.
    BJU INTERNATIONAL, 2012, 109 : 7 - 7